Alzheimer’s progression in Down syndrome appears similar to other genetic, early onset forms of the disease

Dec. 13, 2022
NIH-funded study suggests people with Down syndrome may benefit from Alzheimer’s disease treatments.

Amyloid plaques — protein clumps that are one of the hallmarks of Alzheimer’s disease—occur at roughly the same level in the brains of people with Down syndrome who have Alzheimer’s as they do in people with forms of hereditary, early-onset Alzheimer’s, according to research funded by the National Institutes of Health. The findings suggest that individuals with Alzheimer’s and Down syndrome may benefit from participating in studies on Alzheimer’s therapies aimed at slowing formation of amyloid plaques.

The study was conducted by Beau Ances, M.D., Ph.D., of Washington University in St. Louis, and colleagues from the Dominantly Inherited Alzheimer Network (DIAN) and the Alzheimer’s Biomarkers Consortium–Down Syndrome (ABC-DS). It appears in Lancet Neurology. NIH funding was provided by the National Institute on Aging (NIA), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the Investigation of Co-Occurring Conditions Across the Lifespan to Understand Down Syndrome Project.

For the current study, researchers periodically conducted MRI and amyloid positron emission tomography scans of the brains of people with Down syndrome. They then compared the results to brain scans of people who have early-onset Alzheimer’s disease resulting from inheriting pathogenic variants of the APP gene or the PSEN1 or PSEN2 genes, which code for enzymes that break down amyloid precursor proteins.

The study involved 192 individuals with Down syndrome and 33 sibling controls from the ABC-DS trial. It also involved 265 carriers of either the APPPSEN1, or PSEN2 variants and 169 non-carrier family members who were participants in the NIA-funded DIAN trial, also part of the control group.

Overall, the amount of amyloid burden was similar in the brains of people with Down syndrome to those who carry the gene variants for early-onset forms of Alzheimer’s disease. For both groups, levels of brain amyloid were higher than the control group. In addition, the participants with Down syndrome and early-onset Alzheimer’s who showed signs of cognitive decline on thinking and memory tests had higher levels of amyloid than their counterparts who showed no signs of cognitive decline.

One difference between the two groups was seen in the pattern of brain amyloid plaque formation. The participants who had early-onset Alzheimer’s had plaques in all areas of the cerebral cortex, the outermost layer of the brain. In contrast, the brains of people with Down syndrome did not have plaque deposits in the middle of the occipital lobe, the portion of the cerebral cortex at the back of the brain.

NIH release